Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- “Changing Way of Thinking Necessary among Industry, Government, Academia for Promotion of Drug Discovery”: AZ Chairman Kato
October 25, 2012
- Santen Going on Offensive in Growth Fields in Ophthalmology
October 24, 2012
- More Products, Fewer Facilities Per MR: Novartis Introduces New Marketing System
October 24, 2012
- Kaken Pharmaceutical Files NDA for Efinaconazole, 1st Topical Drug for Onychomycosis in Japan
October 24, 2012
- Former Nycomed CSO to Head General Medicine Drug Discovery Unit of Takeda
October 24, 2012
- COPD Treatment Market to Expand 2.8 Times by 2020 Compared to 2011: Fuji-Keizai
October 24, 2012
- Antiepileptic Drug Fycompa Approved in the US: Eisai
October 24, 2012
- Astellas Launches Mirabegron in US
October 24, 2012
- Astellas Poised for Domestic PIIb Trial of Novel IBS Treatment
October 23, 2012
- Astellas Receives Recommendation for Approval of Mirabegron in Europe
October 23, 2012
- Neuropathic Pain Treatment Offered Funding from JST’s Support Program: Nippon Chemiphar
October 23, 2012
- Astellas Launches Gonax for Full-Fledged Entry into Cancer Field
October 23, 2012
- Takeda Moves Up to 5th, Pfizer 1st in Patent Assets Ranking
October 22, 2012
- Chugai Succeeds in Establishing World's First Stable Cancer Stem Cell Lines
October 22, 2012
- MTPC to Dissolve Capital Alliance with Choseido
October 22, 2012
- Kyowa Kirin Suspends PIIa Study of RTA 402 in Response to Licensor’s Termination of Study
October 22, 2012
- Nexium Dominates No.1, 2 Positions in Both GP, HP Markets in September Prior to Lifting of Ban on Long-Term Prescription: RepTrack Survey
October 19, 2012
- 40% of Doctors Collect Drug Information Via Smartphones: CareNet Survey
October 19, 2012
- Novartis Files for Additional Indication of Pediatric Use for Xolair
October 18, 2012
- Ajinomoto Files NDA for AJH801, 6th Fixed-Dose ARB/CCB Combination in Japan
October 18, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…